"In closing, CEO Doug Ward said: " The past few months have been...

"In closing, CEO Doug Ward said: " The past few months have been critical for Lumos and for FebriDx®,
marked by a series of very significant milestones that are not only advancing our U.S. regulatory pathway
but also laying the foundation for FebriDx® as a true platform diagnostic. The distribution partnership with
PHASE Scientific represents the culmination of years of hard work by our exceptional team. I remain deeply
confident in the tangible benefits of FebriDx® and the meaningful impact it can have on patient care, clinical
decision-making, and broader healthcare system efficiencies."

"Our CLIA Waiver study for FebriDx® continues to progress well, with study completion expected around
August 2025, with our FDA CLIA waiver application expected to be submitted within approximately one
month of completion. Encouragingly, we’ve seen strong early support from U.S. public payors, which we
believe will be the catalyst for broader adoption by private payors in due course."
"I’m sincerely grateful for the continued backing of our two largest shareholders, Tenmile and Ryder Capital.
The non-dilutive funding facility, along with contracted FebriDx® distribution fees and future milestone
payments from our partners, positions Lumos well to meet working capital needs as we advance towards
the anticipated granting of CLIA waiver."

“Looking ahead, we remain firmly focused on our strategic priorities and committed to building a strong,
sustainable business that delivers long-term value for patients, partners, and shareholders alike.”